Business Context and Reporting Period
This Form 8-K Current Report was filed by Acrivon Therapeutics, Inc. on September 16, 2024, covering events reported on September 14, 2024. The filing primarily addresses the presentation of Phase 2 clinical data for ACR-368 at the ESMO Congress 2024, regulatory progress for ACR-2316, and updates on the company's AP3 Interactome platform.
Key Financial Metrics
The filing does not provide a full set of financial statements, revenue, profit, or cash flow data for the current period. However, it references liquidity figures from the most recent quarter:
- Cash, Cash Equivalents, and Investments: $220.4 million as of June 30, 2024.
- Liquidity Outlook: Management expects existing funds to be sufficient to finance operating expenses and capital expenditures into the second half of 2026.
Material Changes and Clinical Updates
The report details significant clinical and regulatory milestones rather than financial changes:
- ACR-368 Phase 2 Data: Presented data from a registrational intent trial in endometrial cancer. In the prospectively-selected OncoSignature-positive cohort (23 efficacy-evaluable patients), a confirmed objective response rate (ORR) of 62.5% was observed. All confirmed responders remained on treatment with a median duration of response not yet reached.
- OncoSignature Validation: Data validated the AP3-based assay, showing clear segregation of responders between OncoSignature-positive and negative arms (p-value = 0.009).
- ACR-2316 Progress: The FDA cleared the Investigational New Drug (IND) application. Clinical sites are activated ahead of schedule, with first-in-human dosing for the Phase 1 study expected in the fourth quarter of 2024.
- Safety Profile: ACR-368 adverse events were limited, transient, and predominantly mechanism-based hematological events, with no long-lasting myelosuppression observed.
Guidance, Outlook, and Risks
Guidance and Outlook: The company reiterated its previous guidance that its cash position of $220.4 million (as of June 30, 2024) will fund operations into the second half of 2026. The company anticipates first-in-human dosing for ACR-2316 in Q4 2024.
Risks and Contingencies: The filing notes that the clinical data presented is based on a data cut-off of July 25, 2024, and includes a small sample size (35 safety-evaluable subjects). The information is furnished under Regulation FD and is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) and the R&D presentation (Exhibit 99.2) for detailed clinical trial statistics.
- Confirm the specific timeline for the ACR-2316 Phase 1 study initiation in Q4 2024.
- Review the company's most recent 10-Q or 10-K for detailed financial statements, as this 8-K only references the June 30, 2024 cash balance.
- Monitor future filings for updates on the duration of response for ACR-368 responders as the trial progresses.